ArticleChest2021
Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension.
Article in Chest, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00370214 (REVEAL Registry™), which is not on this map. Cited by 186 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management
Who cites it
186 citing papers in PubMed, 6 syntheses or guidelines pooled it, 295 citations in OpenAlex.
- Brazilian guidelines for the pharmacological treatment of pulmonary hypertension. Official document of the Brazilian Thoracic Society based on the Grading of Recommendations Assessment, Development, and Evaluation methodology.Respiratory research & clinical practice · 2026Guideline
- Comparative diagnostic accuracy of artificial intelligence-derived risk stratification versus conventional risk stratification methods in pulmonary hypertension patients: a systematic review and meta-analysis.Frontiers in artificial intelligence · 2025Pooled it
- Prognostic Value of Serial Risk Stratification in Adult and Pediatric Pulmonary Arterial Hypertension: A Systematic Review.Journal of the American Heart Association · 2024Pooled it
- Is low-risk status a surrogate outcome in pulmonary arterial hypertension? An analysis of three randomised trials.The Lancet. Respiratory medicine · 2023Pooled it
- Heterogeneity of treatment effects by risk in pulmonary arterial hypertension.The European respiratory journal · 2023Pooled it
- Risk stratification in adult and pediatric pulmonary arterial hypertension: A systematic review.Frontiers in cardiovascular medicine · 2022Pooled it
- Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities.European journal of heart failure · 2024Trial
- Oral Treprostinil is Associated with Improved Survival in FREEDOM-EV and its Open-Label Extension.Advances in therapy · 2024Trial
- Characteristics of Patients with Pulmonary Arterial Hypertension Receiving Selexipag in the SPHERE Registry by Race and Ethnicity.Journal of racial and ethnic health disparities · 2026Observational
- A Team-Based Patient Engagement Approach to Selexipag Initiation and Maintenance in Pulmonary Arterial Hypertension (TEAM PAH): Real-World Dosing Patterns and Persistence Among Patients With and Without a History of Methamphetamine Use.Pulmonary circulation · 2026Article
- CORE-PH: A 3-Component Score for Long-Term Mortality Risk in a Pulmonary Arterial Hypertension Cohort.Diagnostics (Basel, Switzerland) · 2026Article
- Remote exercise assessment in pulmonary hypertension.Current opinion in pulmonary medicine · 2026Review
- Artificial Intelligence and Multi-Omics Approaches in the Precision Management of Pulmonary Hypertension: From Early Diagnosis to Therapeutic Stratification.International journal of molecular sciences · 2026Review
- Natriuretic Peptides as Predictors for the Diagnosis of Pulmonary Hypertension Secondary to Left Heart Disease and for the Assessment of Its Severity.International journal of molecular sciences · 2026Article
- Frailty in Pulmonary Arterial Hypertension: A Cohort Study.Annals of the American Thoracic Society · 2026Article
- Combination of TAPSE/sPAP Ratio and Myocardial Work to Assess Prognosis in Patients with Pulmonary Arterial Hypertension.Journal of cardiovascular development and disease · 2026Article
- Observed Weight Gain in Patients With Pulmonary Arterial Hypertension Treated With Sotatercept.Pulmonary circulation · 2026Article
- Transitions From Parenteral Prostacyclin Analogues to Selexipag in Patients With Pulmonary Arterial Hypertension.Pulmonary circulation · 2026Article
- 3-ERJ open research · 2026Article
- Sequential Add-On Therapy Modifies Mortality Risk Stratification in Group 1.4 Pulmonary Arterial Hypertension: A Real-World, Single-Center Retrospective Cohort Study from Mexico.Journal of clinical medicine · 2026Article
126 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
8 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAchievement of low-risk status is a treatment goal in pulmonary arterial hypertension (PAH). Risk assessment often is performed using multiparameter tools, such as the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) risk calculator. Risk calculators that assess fewer variables without compromising validity may expedite risk assessment in the routine clinic setting. We describe the development and validation of REVEAL Lite 2, an abridged version of REVEAL 2.0. RESEARCH QUESTION: Can a simplified version of the REVEAL 2.0 risk assessment calculator for patients with PAH be developed and validated? STUDY DESIGN AND
methodsREVEAL Lite 2 includes six noninvasive variables-functional class (FC), vital signs (systolic BP [SBP] and heart rate), 6-min walk distance (6MWD), brain natriuretic peptide (BNP)/N-terminal prohormone of brain natriuretic peptide (NT-proBNP), and renal insufficiency (by estimated glomerular filtration rate [eGFR])-and was validated in a series of analyses (Kaplan-Meier, concordance index, Cox proportional hazard model, and multivariate analysis).
resultsREVEAL Lite 2 approximates REVEAL 2.0 at discriminating low, intermediate, and high risk for 1-year mortality in patients in the REVEAL registry. The model indicated that the most highly predictive REVEAL Lite 2 parameter was BNP/NT-proBNP, followed by 6MWD and FC. Even if multiple, less predictive variables (heart rate, SBP, eGFR) were missing, REVEAL Lite 2 still discriminated among risk groups.
interpretationREVEAL Lite 2, an abridged version of REVEAL 2.0, provides a simplified method of risk assessment that can be implemented routinely in daily clinical practice. REVEAL Lite 2 is a robust tool that provides discrimination among patients at low, intermediate, and high risk of 1-year mortality. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00370214; URL: www.clinicaltrials.gov.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.